Da Volterra

Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiome & oncology fields.

[Da Volterra @DaVolterra]

#ESMO22: Don’t miss Dr. Messaoudene‘s (@CRCHUM, Montreal) mini oral presentation on Sunday 11.09 at 15:25 CET (1663MO): key preclinical results showing the importance of DAV132 in #immunooncology will be presented
https://t.co/QzjnIuUbAi
#cancer #immunotherapy #microbiome

[Da Volterra @DaVolterra]

This article in @Nature highlights the importance of the #microbiome in response to #cancer treatment: “Long-term responders had a more diverse tumour microbiome than did those who survived less than five years”! https://t.co/QCe7JQJu9j

[Da Volterra @DaVolterra]

This Wednesday, Jean De Gunzburg, CSO of Da Volterra, will speak at the 8th Annual Microbiome Connect Europe 2022 on Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy, on July 6th, at 11.30am CET. Don’t miss it! https://t.co/6XsCHT8bKv
@KR_Microbiome

[Da Volterra @DaVolterra]

Happy 2022 World Microbiome Day! @DaVolterra, we are developing gut microbiome-protective therapies and we believe that preserving the #microbiome of #cancer patients is critical to their treatment response and survival. https://t.co/b71MeRUjmU
@WMicrobiomeDay

[Da Volterra @DaVolterra]

Da Volterra's CSO, Jean de Gunzburg, is attending the 7th Microbiome Movement Drug Development Summit on June 21-24 in Boston, the most comprehensive forum for microbiome drug developers. https://t.co/fupoilJFEM @MicrobiomeDaily
#microbiome #MicrobiomeMovement #oncology #Biotech

[Da Volterra @DaVolterra]

These June 13-16, Da Volterra’s BD Manager, Julie Cervesi, will be at BIO 2022 in San Diego with exciting news to share during the world’s largest leading biotech convention. Looking forward to meeting potential partners! https://t.co/vjBNe5L8WP #BIO2022 #Microbiome #Cancer

[Da Volterra @DaVolterra]

Don’t miss Da Volterra’s BD Manager, Julie Cervesi, poster presentation on 'Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with ICIs’ at ASCO on June 5, 8:00-11:00 AM CDT https://t.co/GakrOSdPdd

[Da Volterra @DaVolterra]

Meet with us at BIO 2022 in San Diego, June 13-16! Find Da Volterra in the partnering system for potential meetings at the largest gathering of the global biotech community! https://t.co/DKctUxN9x6 @businessfrance

[Da Volterra @DaVolterra]

Da Volterra will participate to ASCO Annual Meeting in Chicago and present a poster: ‘Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitor’ https://t.co/b8TEeMZEkq

[Da Volterra @DaVolterra]

Da Volterra delighted to announce positive preclinical results in immuno-oncology with DAV132, a revolutionary gut protector https://t.co/S82QQM3LRy #Biotech #Immunotherapy #Microbiome #Cancer

[Da Volterra @DaVolterra]

https://t.co/Tb3Agqma8O

[Da Volterra @DaVolterra]

Don’t miss Dr Routy’s presentation @AACR on April 11 at 8pm CET: he will present non-clinical results showing the crucial role of the gut microbiome on response to anti-PD-1 and the ability of DAV132 to maintain the full efficacy of anti-PD-1 by protecting the @microbiome!

[Da Volterra @DaVolterra]

Exciting new science in @NatureMedicine for CAR-T patients, perturbations in the intestinal #Microbiome are associated with lower survival and increased neurotoxicity after CAR-T cell therapy in patients with B cell malignancies. https://t.co/3snaO6C5Ct #Cancer

[Da Volterra @DaVolterra]

Don’t miss the presentation of Jean de Gunzburg, Da Volterra's CSO, on preserving the intestinal microbiome from antibiotic-induced dysbiosis with DAV132, an effective & safe solution for #cancer patients during last PRI Annual Event in @MicrobiomeTimes. https://t.co/ePNIRVZ1Ud

[Da Volterra @DaVolterra]

The whole @DaVolterra team is supporting #WorldCancerDay to reimagine a world where millions of cancer deaths are saved and access to life-saving cancer treatment and care is equitable for all! https://t.co/OeBTR31Ems #CloseTheCareGap

[BEAM Alliance @AllianceBEAM]

We welcome 2022 as a new challenge to learn from past mistakes and fight #AMR. Read our reflection paper on PULL incentives which explains why a hybrid Transferable Exclusivity Extension & Subscription model would be a solution for the #EU27 to consider. https://t.co/enCUJZh7s3

[BEAM Alliance @AllianceBEAM]

The first comprehensive analysis of the global impact of AMR estimates resistance itself caused 1.27 million deaths in 2019. A shocking leap from previous estimates of 700k deaths a year. It is clear - AMR is one of the greatest threats to public health. https://t.co/Z8o02Lkj5X

[Oliver Cornely @CornelyOliver]

New OA Publication @BSACandJAC showing #DAV132 preserved intestinal #microbiota diversity and C. difficile colonization resistance: https://t.co/IkkDKwmNec @mjvehreschild

[Da Volterra @DaVolterra]

Da Volterra glad to announce the publication of its positive Phase 2 results in the Journal of Antimicrobial Chemotherapy: it is a considerable achievement for DAV132 and a leap towards commercialization. Read the article: https://t.co/WMWZxcwtIN
#Microbiome #Biotechs #Health

[Da Volterra @DaVolterra]

Da Volterra wishes you #HappyHolidays and a prosperous & healthy #2022! #Seasonsgreetings to you all!